Stockscreener 앱 받기
7.79
2.87%
-0.23
시간 외 거래:
7.75
-0.04
-0.51%
전일 마감가:
$8.02
열려 있는:
$7.96
하루 거래량:
4.40M
Relative Volume:
1.04
시가총액:
$1.99B
수익:
$885.72M
순이익/손실:
$-457.98M
주가수익비율:
-4.385
EPS:
-1.7765
순현금흐름:
$293.05M
1주 성능:
-8.89%
1개월 성능:
-7.59%
6개월 성능:
-18.17%
1년 성능:
+15.92%
1일 변동 폭
$7.74
$8.015
1주일 범위
$7.74
$8.55
52주 변동 폭
$6.23
$11.22
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.79 | 1.99B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-07-13 | 재개 | JP Morgan | Neutral |
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders - BioBuzz
BioCryst Pharmaceuticals stock fell 1.85 percent on October 6 - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals Inc (BO1.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BioCryst Pharmaceuticals stock gets a new science board - AD HOC NEWS
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board - www.marketscreener.com
BioCryst forms scientific advisory board for R&D strategy By Investing.com - Investing.com India
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
JPMorgan raises target for BioCryst Pharmaceuticals stock - AD HOC NEWS
BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo
BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus
J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Claude AI Just Bought These 2 Pharma Stocks - finance.yahoo.com
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - finance.yahoo.com
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS
Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance
Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Yahoo Finance
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - Yahoo Finance
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com India
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - marketscreener.com
BioCryst to Present at Upcoming Investor Conference - GlobeNewswire
BioCryst to Present at Upcoming Investor Conference - Yahoo Finance
Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan
BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오크리스트 주식 (BCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Amy McKee | Director |
May 18 '26 |
Proposed Sale |
8.94 |
11,180 |
99,906 |
0 |
| Barnes Alane P | Chief Legal Officer |
May 13 '26 |
Sale |
9.54 |
62,500 |
596,250 |
400,703 |
| Barnes Alane P | Chief Legal Officer |
May 13 '26 |
Option Exercise |
5.04 |
62,500 |
315,000 |
463,203 |
| Barnes Alane P | Officer |
May 13 '26 |
Proposed Sale |
9.54 |
62,500 |
596,250 |
0 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Proposed Sale |
10.11 |
49,933 |
504,620 |
0 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Option Exercise |
6.30 |
49,933 |
314,578 |
115,285 |
| HEGGIE THERESA | Director |
Mar 20 '26 |
Sale |
10.11 |
49,933 |
504,823 |
65,352 |
| Barnes Alane P | Chief Legal Officer |
Mar 16 '26 |
Option Exercise |
5.51 |
150,000 |
826,500 |
550,703 |
| Barnes Alane P | Chief Legal Officer |
Mar 16 '26 |
Sale |
9.15 |
150,000 |
1,372,500 |
400,703 |
| Barnes Alane P | Officer |
Mar 16 '26 |
Proposed Sale |
9.15 |
150,000 |
1,372,007 |
0 |
2.82%
2.38%
자본화:
|
볼륨(24시간):